Crucell's Supervisory Board Nominates Mr. W. Burns, Mr. J. Shannon and Mr. G. Siber as New Board Members
Crucell N.V. announced the nomination of Mr. William (Bill) Burns, Mr. James Shannon and Mr. George Siber to join its Supervisory Board. The Supervisory Board of Crucell has nominated Mr. Burns, Mr. Shannon and Mr. Siber as new members of the Board, to be presented to Crucell's shareholders at the Company's AGM on June 4, 2010.
Mr. Burns (1947), a British national, has built a distinguished track record in the pharmaceutical industry over the last 40 years. Most recently Mr. Burns served as the CEO of the Pharmaceuticals Division of Roche. Mr. Burns worked at Roche since 1986, where in 1991 he moved from being Head of Pharma UK to being responsible for Global Business Development and Strategic Marketing, based in Switzerland. Mr. Burns' responsibilities also included all international commercial operations. Mr. Burns joined Roche's Corporate Executive Committee in 2000 and headed the Pharmaceutical Division of the company worldwide for 8 years. He stepped down as CEO Pharmaceuticals Division in December 2009. Prior to Roche Mr. Burns worked at Beecham Pharmaceuticals where he started as a management trainee in 1969. He spent the next 17 years with Beecham in a variety of roles of increasing responsibility, based in the UK and Japan. Mr. Burns graduated from Strathclyde University, Scotland, with a B.A. (Honours Degree) in Business Economics.
Mr. Burns represented Roche on the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and was Chairman of Interpharma, the Swiss research companies' trade association. Mr. Burns has extensive experience in biotechnology and served as a board member of Genentech and is currently a member of the Board of Roche Holding AG and Chugai Pharmaceutical Co., Ltd.
Mr. Shannon (1956), a British national, with over 20 years of experience in senior development positions, most recently served as Head of Global Development at Novartis Pharma AG in Basel. He joined Sandoz AG in Basel as Head of Regulatory Affairs and on the announcement of the merger between Ciba-Geigy AG and Sandoz, Mr. Shannon headed the Research & Development integration office to create the newly formed Research & Development groups at Novartis. Following the successful global integration of the two companies, Mr. Shannon returned to the USA to head the Cardiovascular Strategic team of Novartis for the launch phase of Diovan, which ultimately became Novartis' largest product. Subsequently he held a number of other senior development positions at Novartis ultimately leading to his appointment as Head of Global Development in 2005. Mr. Shannon retired from Novartis in 2008. Before joining Novartis, Mr. Shannon held various senior positions in clinical and product development at Sterling Winthrop Inc. and was Senior Vice President of Clinical Development for Sterling during the alliance with Sanofi which saw the late stage development of clopidogrel and irbesartan. He left shortly after the acquisition of Sterling by Sanofi in 1994. Mr. Shannon started his professional career with approximately seven years in clinical practice, after finishing his medical studies in Ireland and his undergraduate and post-graduate degrees from Queens University, Belfast, where he trained in medicine and cardiology.
Mr. Shannon has been involved in the development and registration of many successful medicines, including Diovan, Tekturna®, Gleevec®, Femara®, Zometa®, Aclasta, Xolair®, and Plavix®. At present Mr. Shannon holds the position of President and CEO of Cerimon Pharmaceuticals, Inc. and serves on the Boards of Arch Therapeutics; Endocyte Inc; Mannkind Corporation and Xanodyne Pharmaceuticals, Inc.
Mr. Siber (1944), an American national, is regarded to be one of the leading global authorities in vaccines. Mr. Siber completed his medical degree at McGill University in Canada. From 1970 to 1975, Mr. Siber went through intensive medical training in internal medicine and infectious diseases at Rush Medical Center in Chicago and Beth Israel and Children's Hospital at Harvard Medical School in Boston. Mr. Siber has extensive drug development experience and has been developing vaccines since his days in the public health service, a career of 35 years (post academic work). Previously Mr. Siber was the Executive Vice President and Chief Scientific Officer of Wyeth Vaccines. Prior to joining Wyeth, Mr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. At Wyeth, Mr. Siber has overseen vaccine research and development for 10 years. Products developed under his leadership at Wyeth include Acel-Immune, RotaShield®, Meningitec®, Prevenar 7, Prevenar 13, and FluMist®, in collaboration with MedImmune. Additionally, while in Massachusetts, Mr. Siber led the research, the development, and the approval of CytoGam® (CMV Immune Globulin) and RespiGam® (RSV Immune Globulin), both marketed by MedImmune. RespiGam® is the precursor product to Synagis®, the first monoclonal antibody to an infectious disease.
Mr. Siber currently serves on numerous advisory committees including those of the PATH's Pneumococcal Vaccine Project, the Malaria Vaccine Initiative, the Gates Maternal Immunization Program, the Stop TB Task Force and the Scientific Advisory Board of several vaccine companies, including Novartis Vaccines and Diagnostics, LigoCyte Pharmaceuticals, Inc. and Variation Biosciences. Mr. Siber was named to the National Advisory Allergy and Infectious Diseases Council in 2010. Mr. Siber is currently serving as Executive Chairman of Genocea Biosciences and as Non-executive Director of Selecta Biosciences, Inc., both in Boston.
Other news from the department people
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
